Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Continuous infusion versus intermittent administration of meropenem in critically ill patients
Autore:
Thalhammer, F; Traunmuller, F; El Menyawi, I; Frass, M; Hollenstein, UM; Locker, GJ; Stoiser, B; Staudinger, T; Thalhammer-Scherrer, R; Burgmann, H;
Indirizzi:
Univ Vienna, Dept Internal Med 1, Div Infect Dis, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 Div Infect Dis, A-1090 Vienna, Austria Univ Vienna, Dept Internal Med 1, Intens Care Unit, A-1090 Vienna, AustriaUniv Vienna Vienna Austria A-1090 tens Care Unit, A-1090 Vienna, Austria Univ Vienna, Dept Lab Med, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 , Dept Lab Med, A-1090 Vienna, Austria
Titolo Testata:
Journal of antimicrobial chemotherapy
fascicolo: 4, volume: 43, anno: 1999,
pagine: 523 - 527
Fonte:
ISI
Lingua:
ENG
Soggetto:
BETA-LACTAM ANTIBIOTICS; CEFTAZIDIME; PHARMACOKINETICS; INFECTIONS; PARAMETERS; VANCOMYCIN; THERAPY; MICE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Thalhammer, F Univ Vienna, Dept Internal Med 1, Div Infect Dis, WaehringerGuertel 18-20, Univ Vienna Waehringer Guertel 18-20 Vienna Austria A-1090
Citazione:
F. Thalhammer et al., "Continuous infusion versus intermittent administration of meropenem in critically ill patients", J ANTIMICRO, 43(4), 1999, pp. 523-527

Abstract

This prospective crossover study compared the pharmacokinetics of meropenem by continuous infusion and by intermittent administration in critically ill patients. Fifteen patients were randomized to receive meropenem either as a 2 g iv loading dose, followed by a 3 g continuous infusion (CI) over 24h, or by intermittent administration (IA) of 2 g iv every 8 h (q8h). Each regimen was followed for a period of 2 days, succeeded by crossover to the alternative regimen for the same period. Pharmacokinetic parameters (mean +/- SD) of CI included the following: concentration at steady state (C-SS) was 11.9 +/- 5.0 mg/L; area under the curve (AUC) was 117.5 +/- 12.9 mg/L.h. The maximum and minimum serum concentrations of meropenem (C-max, C-min) and total meropenem clearance (CItot) for IA were 110.1 +/- 6.9 mg/L, 8.5 +/- 1.0 mg/L and 9.4 +/- 1.2 L/h, respectively. The AUC during the IA regimenwas larger than the AUC during CI (P < 0.001). In both treatment groups, meropenem serum concentrations remained above the MICs for the most common bacterial pathogens. We conclude that CI of meropenem is equivalent to the IA regimen and is therefore suitable for treating critically ill patients. Further studies are necessary to compare the clinical effects of CI and IA in this patient group.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 18:59:12